Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Market Cap	$815.53M	P/E Ratio	N/A
52W High	$24.05	52W Low	$6.42
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	91.9%
Overall Score	61	Value Score	60
Quality Score	34	Technical Score	91

EPS Current Est	$-1.99	EPS Next Est	$-2.26
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TYRA	$22.63	-0.79%	259.24K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TYRA	$22.63	-0.8%	259.24K
3
4
5
6

TYRA

TYRA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Tyra Biosciences Inc. Data in Excel

Get Tyra Biosciences Inc. Data in Excel